Showing results (121-130 of 168) with videos related to
Sort By:
Pageof 17
Archives Des Maladies Du Coeur Et Des Vaisseaux|July 26, 2002
[Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study]T Simon, M Mary-Krause, C Funck-Brentano, et al.British Journal of Clinical Pharmacology|September 1, 1996
Influence of liver cirrhosis on sertraline pharmacokineticsJ L Démolis, P Angebaud, J D Grangé, et al.British Journal of Clinical Pharmacology|October 6, 1999
Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteersI Ragueneau, J M Poirier, N Radembino, et al.Circulation|February 1, 1991
Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humansC Funck-Brentano, Y Kibleur, F Le Coz, et al.Clinical Pharmacology and Therapeutics|September 1, 1991
Influence of amiodarone on genetically determined drug metabolism in humansC Funck-Brentano, E Jacqz-Aigrain, A Leenhardt, et al.British Journal of Clinical Pharmacology|November 14, 1997
Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteersJ L Démolis, C Martel, C Funck-Brentano, et al.Pharmacogenetics|November 3, 2001
Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizersC Verstuyft, S Morin, A Robert, et al.Journal of Hepatology|January 1, 1985
Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosisJ C Barbare, R E Poupon, P Jaillon, et al.Clinical Pharmacology and Therapeutics|June 1, 1997
Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humansL Becquemont, I Ragueneau, M A Le Bot, et al.Fundamental & Clinical Pharmacology|January 11, 2000
Lymphocyte P-glycoprotein expression and activity before and after rifampicin in manL Becquemont, M Camus, V Eschwege, et al.Pageof 17